Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (29)

I-01Annika Schneider

Physiologically based pharmacokinetic modeling – application for renal and hepatic impairment

Wednesday 10:10-11:40

I-18Konstantinos Stamatopoulos

A Population based PBPK Modelling for the Prediction of Bile Salts Disposition within GI Luminal Fluids – Towards a Mechanistic Bile Salts Model

Wednesday 10:10-11:40

I-36Kota Toshimoto

Application of virtual clinical studies to predict the effect of inter-individual differences on the drug/metabolites exposures in the blood and target organs leading to different pharmacological and toxicological effect

Wednesday 10:10-11:40

I-39Denise Feick

Physiologically-based pharmacokinetic modeling of gemfibrozil drug-drug interactions with the CYP2C8 victim drugs repaglinide and pioglitazone

Wednesday 10:10-11:40

I-45Erno van Schaick

Simulations of the paliperidone pharmacokinetics of intramuscular long-acting injectable microsuspensions of paliperidone palmitate in rats using a mechanistic model

Wednesday 10:10-11:40

II-07Kevin Feng

Selecting in vitro dissolution tests using population pharmacokinetic modelling to help bioequivalence studies

Wednesday 15:50-17:20

II-35Silvia Grandoni

Evaluating the inclusion of the particle size distribution in the lung dissolution model of a WB-PBPK model to describe the pharmacokinetics of inhaled polydisperse drugs.

Wednesday 15:50-17:20

II-38Felix Hammann

Whole-body physiology pharmacokinetic modeling of flip-flop behavior of oral oxycodone solution in pediatric patients 5-16 years old

Wednesday 15:50-17:20

II-39Niklas Hartung

A size- and location-structured model for pulmonary absorption, elimination and dissolution of an orally inhaled drug

Wednesday 15:50-17:20

II-47Wilhelm Huisinga

Cell-level based tumor cPBPK model to study mAb distribution within solid tumors and implications for efficacious treatment

Wednesday 15:50-17:20

II-50Ibrahim Ince

A Population Physiologically-Based Pharmacokinetic Model for prediction of pharmacokinetics of small molecule drugs in healthy Japanese adults: Bridging PBPK from Caucasian to Japanese ethnicity

Wednesday 15:50-17:20

II-66Tobias Kanacher

Development of a whole body physiologically-based pharmacokinetic (PBPK) model for inhaled salmeterol to predict interactions with CYP3A4 inhibitors

Wednesday 15:50-17:20

II-68Eleni Karatza

Mathematical modeling of gastric emptying: a joint model for losartan and its active metabolite EXP-3174

Wednesday 15:50-17:20

III-03Amais Ahmad

Evaluation of Prediction Performance of In Silico PBPK models of oral drug absorption

Thursday 09:55-11:30

III-07Muhammad Waqar Ashraf

A semi-PBPK model to describe the mechanism based drug-drug interaction between S-ketamine and ticlopidine in healthy human volunteers.

Thursday 09:55-11:30

III-11Vanessa Baier

Developing a physiology-based model of bile acid metabolism in men

Thursday 09:55-11:30

III-12Pavel Balazki

A Physiologically-based Quantitative Systems Pharmacology model of the incretin hormones GLP-1 and GIP

Thursday 09:55-11:30

III-18Roberta Bartolucci

A PBPK model for the study of Azathioprine pharmacokinetics in rats and prediction in humans

Thursday 09:55-11:30

III-31Hannah Britz

Physiologically-based pharmacokinetic (PBPK) modeling of the strong CYP1A2 inhibitor fluvoxamine

Thursday 09:55-11:30

III-48Manoranjenni Chetty

Antidepressants, anxiolytics and statins: prediction of exposure changes due to aging

Thursday 09:55-11:30

III-59André Dallmann

Characterization of paracetamol hepatotoxicity during pregnancy through physiologically-based pharmacokinetic modeling

Thursday 09:55-11:30

III-65Mailys De Sousa Mendes

Mechanistic modelling of in-vitro bidirectional permeability studies and in vivo absorption of metoprolol

Thursday 09:55-11:30

III-68

A Mechanistic Cellular Disposition Model of Bile Acid Handling in Sandwich-Cultured Human Hepatocytes

Thursday 09:55-11:30

IV-23Jialin Mao

PBPK modelling of drug-drug interactions driven by moderate CYP3A inducers

Thursday 15:10-16:40

IV-30Matilde Merino-Sanjuán

Evaluation of the impact of undernourishment on the intestinal absorption of gefitinib in rats.

Thursday 15:10-16:40

IV-44Andrés Olivares-Morales

Switching from immediate release to modified release can have an impact on intestinal drug-drug interactions: A PBPK simulation study using oxybutynin as a case example

Thursday 15:10-16:40

IV-48Kwan Cheol Pak

Physiologically based pharmacokinetic modeling of Herceptin and human pharmacokinetic prediction

Thursday 15:10-16:40

IV-61Eduard Schmulenson

A physiologically-based pharmacokinetic modeling approach to assess the impact of chronic kidney disease

Thursday 15:10-16:40

IV-70Christer Rimmler

Evaluating New Dosing Strategies for the Use of Cefuroxime in Perioperative Antibiotic Prophylaxis using PBPK

Thursday 15:10-16:40